The goal of this observation is to assess the time course of holistic extended periorbital rejuvenation using botulinum toxin A, cross-linked hyaluronic acid and polynucleotides corresponding to the application in routine practice in adults. It will also document the safety of treatment procedure and patient satisfaction.
The main questions it aims to answer are:
* How does a holistic extended periorbital rejuvenation procedure using botulinum toxin A, cross-linked hyaluronic acid filler, and polynucleotides change skin wrinkling around the eye area over time (particularly after 8 and 22 weeks)?
* How does the treatment affect the severity of dynamic glabellar lines at 8 and 22 weeks?
* Does the procedure improve midface volume deficiency after 8 and 22 weeks?
* How satisfied are participants with the overall rejuvenation treatment?
The investigator will observe the combination treatment of a drug Letybo® and medical devices PhilArt® Eye and Saypha® Volume Plus Lidocaine within their approved indications (non-interventional study, on-label use). The combination treatment aims to rejuvenate and improve the eye area holistically in patients coming routinely to the clinic.
Participants will:
* take PhilArt® Eye on Week 0 (Baseline), 3 and 6; Saypha® Volume Plus Lidocaine on Week 0 (Baseline); Letybo® on Week 6.
* visit the clinic on Week 0 (Baseline), 3, 6, 8 and 22 as per clinical practice for checkups and satisfaction assessment.

开始日期2025-09-02

申办/合作机构

Croma-Pharma GmbH

CTIS2024-512349-17-00

/ Not yet recruiting临床2期

A prospective, randomized, evaluator- and subject blinded, multi-center investigation to assess efficacy and safety of three different dosages of the same injection pattern of LetibotulinumtoxinA in the treatment of moderate and severe horizontal forehead lines

开始日期2024-11-06

申办/合作机构

Croma-Pharma GmbH

NCT07374965

/ CompletedN/AIIT

A Prospective, Non-interventional, Single-Centre Study Assessing the Efficacy of a Holistic Upper Face Treatment With Botulinum Neurotoxin A

The goal of this observational study is to learn about the safety, tolerability, and effectiveness of Letibotulinumtoxin A for the holistic treatment of the upper face in adults under 75 years old with moderate to severe upper facial lines, including glabellar lines, forehead lines, and lateral canthal lines.
The main questions it aims to answer are:
* Does Letibotulinumtoxin A safely and effectively reduce the severity of glabellar lines, forehead lines, and lateral canthal lines in adults under 75?
* How well is the treatment tolerated in everyday clinical practice?
* What is the patient satisfaction with holistic upper face treatment using Letibotulinumtoxin A?
Participants will:
* receive Letibotulinumtoxin A injections in the upper face, including glabellar lines, forehead lines, and lateral canthal lines.
* be observed and followed up to assess the severity of wrinkles, duration of effect, and patient satisfaction.
* report any adverse effects experienced during or after treatment.

开始日期2024-01-29

申办/合作机构

Croma-Pharma GmbH

100 项与 A型肉毒毒素 (Hugel) 相关的临床结果

登录后查看更多信息

100 项与 A型肉毒毒素 (Hugel) 相关的转化医学

登录后查看更多信息

100 项与 A型肉毒毒素 (Hugel) 相关的专利（医药）

登录后查看更多信息

项与 A型肉毒毒素 (Hugel) 相关的文献（医药）

2026-07-01·AESTHETIC PLASTIC SURGERY

Efficacy and Safety of LetibotulinumtoxinA Injection for Trapezius Hypertrophy: A Prospective, Randomized, Double-Blind Trial

Article

作者: Kim, Tae Hyung ; Jeong, Woo Shik ; Kang, Hyun Il ; Lee, Seok Joon

BACKGROUND:

Trapezius hypertrophy is a significant aesthetic concern among women. Botulinum toxin has emerged as a potential treatment option for this condition. In this study, we conducted a prospective, randomized, double-blind trial to evaluate the effectiveness and safety of letibotulinumtoxinA specifically for women.

METHODS:

We conducted a prospective study between July 2022 and June 2023, recruiting 20 patients seeking treatment for trapezius hypertrophy. LetibotulinumtoxinA (Botulax®) was used as the neurotoxin. The patients were randomized into group A (n = 10, 40 units) and group B (n = 10, 80 units). Each group received different doses of toxin at 10 injection points along the trapezius muscle.

RESULTS:

We analyzed the contour changes in two groups and calculated the average area before and after treatment. After 12 weeks post-treatment, both groups demonstrated a decrease in the trapezius area with statistically significant differences (p = 0.011, p = 0.005). The median satisfactory score was 4, indicating a moderate level of satisfaction in both groups. No statistically significant differences or complications were observed between the groups.

CONCLUSION:

LetibotulinumtoxinA for trapezius hypertrophy demonstrated efficacy with no differences between two experimental groups. Aesthetic concerns were addressed, enhancing shoulder and neck appearance with a high degree of satisfaction.

LEVEL OF EVIDENCE I:

This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

2026-06-01·JOURNAL OF NEURAL TRANSMISSION

Korean botulinum toxins

Review

作者: Kim, Nayoung ; Dressler, Dirk ; Adib Saberi, Fereshte ; Johnson, Eric A

Abstract:

Botulinum toxin (BT) is used therapeutically since the late 1980s. For many years, BT drugs were provided by a small group of manufacturers from Europe and the United States. As BT’s use for aesthetic purposes surged, numerous new manufacturers entered the field, particularly from Korea. We want to give an overview about the rapidly expanding and diversifying BT landscape in Korea. Altogether, there are 15 Korean manufacturers of 19 BT drugs registered in Korea, mainly for aesthetic indications. There are 2 Class 1 drugs from 2 Korean manufacturers registered in Korea for export, domestic use and registered in the USA and Europe. These are PrabotulinumtoxinA (Daewoong/Evolus) and LetibotulinumtoxinA (Hugel/Croma Pharma). There are 12 Class 2 drugs from 10 Korean manufacturers registered in Korea for export and domestic use, including Neuronox ® , the first Korean BT drug registered in 2006, NivobotulinumtoxinA/Innotox ® , the world-wide first liquid BT type A preparation and Coretox ® , the world-wide second BT drug without complexing proteins. Innotox ® and Toxsta ® are currently performing clinical studies in the USA. Additionally, there are 5 Class 3 BT drugs from 5 Korean manufacturers registered in Korea for export use only. 5 Korean manufacturers have 5 drug projects in Korea in advanced development phases. With this, Korea is now the country with the worldwide largest number of BT manufacturers and BT drugs.

2026-05-01·AESTHETIC PLASTIC SURGERY

Efficacy and Safety of LetibotulinumtoxinA for the Treatment of Moderate-to-Severe Glabellar Lines: A Systematic Review and Meta-Analysis of RCTs

Review

作者: Masood, Saad ; Khan, Rao Sikandar Shamim ; Sohail, Sayyam ; Minhas, Umm E Aimen ; Masood, Musa

BACKGROUND:

Botulinum toxin type A injections are widely used for the aesthetic treatment of glabellar lines; however, data on the efficacy and safety of newer formulations remain limited.

AIM:

This systematic review and meta-analysis aims to assess the efficacy and safety of the novel botulinum toxin LetibotulinumtoxinA-wlbg compared to placebo for treating moderate-to-severe glabellar lines.

METHODS:

A systematic literature search was conducted to identify randomized controlled trials (RCTs) comparing LetibotulinumtoxinA-wlbg with placebo in adults. A meta-analysis was performed using random-effects models, and the Cochrane RoB-2 tool was used to assess the risk of bias.

RESULTS:

Three RCTs including 1272 patients were analyzed. LetibotulinumtoxinA-wlbg was significantly more effective than placebo for the primary outcome, the composite responder rate at week 4 (risk ratio [RR] = 59.47; 95% CI: 14.95, 236.52). Sustained efficacy was observed at weeks 12 and 16, with significant improvements also seen in investigator-assessed, subject-assessed, and psychological outcomes. The safety analysis revealed no significant increase in the risk of serious, non-serious, or overall treatment-emergent adverse events.

CONCLUSIONS:

LetibotulinumtoxinA-wlbg is an efficacious and well-tolerated treatment for moderate-to-severe glabellar lines. The therapeutic effect is durable, with statistically significant efficacy maintained at 12 and 16 weeks post-treatment. Treatment results in a significant improvement in patients' psychological well-being related to their facial appearance. The safety profile is favorable, with no statistically significant increase in the risk of serious or non-serious adverse events compared to placebo. Further research, including direct head-to-head trials, is warranted to establish its comparative effectiveness.

LEVEL OF EVIDENCE I:

项与 A型肉毒毒素 (Hugel) 相关的新闻（医药）

2026-09-01

·ZAKER

双主业共振 , 医美与创新药蓄势待发 , 这家医药公司中期业绩亮眼。

用制药企业的严谨与创新，打造中国领先医美及生物制药企业。2026 年上半年，四环医药整体经营业绩实现大幅跃升，核心财务指标全线向好，" 医美 + 创新药 " 双主业协同发展格局进一步巩固。2026 年上半年，公司总收益达到 11.61 亿元，同比增长 1%；税前溢利 3.66 亿元，同比大幅提升 133%；期内溢利 2.13 亿元，同比增长 221%；本公司拥有人应占溢利 2.25 亿元，同比增长 119%。业绩增长主要来自医美业务持续贡献核心盈利、创新药业务大幅减亏，叠加非经营性资产处置收益及投资收益共同推动。报告期内，" 医美 + 创新药 " 两大核心业务占比已达到约 80%，业务结构优化成效显著。分业务来看，医美业务收益 6.93 亿元，同比增长 18.5%；轩竹业务收益 0.69 亿元，同比大增 288%；惠升及其他业务收益 1.92 亿元，同比增长 376%；仿制药业务受集采政策影响，实现收益 2.06 亿元，同比下降 59%。1、医美板块继续担当集团核心利润引擎医美板块收入占比从 51% 提升至 60%，同比增加 9 个百分点，经营质量持续优化。公司完成战略升级，从单纯销售产品转型为一站式解决方案服务商，构建起产品、研产、渠道三大核心竞争壁垒。产品端，乐提葆上半年终端销量稳居国内肉毒素市场第一梯队，童颜针新增 6 款规格获批，销量跻身国内行业前列；黑曜双波加速入院，连续 5 个月蝉联黄金微针品牌第一。企业搭建高低搭配水光产品体系，依靠精细化运营规避价格内卷，稳定产品毛利。研产层面，借助 AI 赋能研发，储备 40 余项在研优质管线，在 PHA 新材料赛道拥有独家技术优势；持续推进海外市场准入，将旗下医美运营主体渼颜空间持股比例提升至 90%，配套管理层股权激励，自研产品启动欧盟市场注册，持续增厚归母利润。渠道方面，近 200 人的专业营销团队，联动 9000 余家合作医疗机构，业务覆盖全国 34 个省份、370 余个城市，实现国内 TOP500 头部医美机构 100% 覆盖，1500 余家重点核心医院纳入合作网络。童颜针再生产品覆盖超 2000 家机构，冻妍深度渗透千家下沉市场机构，渠道下沉成果显现。作为行业内唯一实现轻医美全品类合规布局的企业，四环医药手握 60 余款产品，覆盖填充、塑形、光电及皮肤管理全品类，拥有肉毒毒素、再生材料、动能素、双波射频微针、玻尿酸等完整产品线。在此基础上推出三大联合治疗方案：" 回颜臻 + 冻妍 " 魔力童颜综合抗衰标杆方案；以 " 乐提葆 " 为核心的 " 乐葆 +" 全品类协同方案；" 铂安润 + 倾妍 + 斯弗妍 " 组成的轮廓固定高阶抗衰方案。通过产品与设备组合，实现分层、分时、分部位精细化抗衰管理，跳出单品价格内卷，构筑差异化竞争壁垒。2、医药板块整体实现爆发式增长医药板块亏损同比大幅收窄 32.1%。集团两大创新药平台轩竹生物、惠升生物均取得重要进展，企业正由 Biotech 加速迈向具备商业化兑现能力的 Biopharma。轩竹生物作为集团核心创新药平台，2026 上半年实现收入 0.69 亿元，同比增长 288%。核心产品获得医保、权威指南及顶刊多重背书，医院渗透率持续提升。安久卫完成医保续约且价格保持稳定，RE、HP 新适应症拓展打开长期市场空间；轩悦宁一线适应症获批，成为国内唯一覆盖乳腺癌全疗程的同类产品；轩菲宁成功获批，落地海外 BD 合作，贡献国际商业化增量。研发端，轩竹生物搭建大小分子 + 小核酸 + 临床多技术平台，依托自有 TCE 与 AI 平台开发多款双抗，已实现 6 项 NDA 申报。海外拓展方面，轩竹生物两款核心创新药落地中东北非独家授权，联动 15 国合作伙伴推进商业化落地。资本层面，轩竹生物顺利完成 H 股全流通并成功纳入港股通，股票流动性得到显著提升。惠升生物深耕糖尿病及并发症赛道，累计获批品种 18 个、获批规格 27 个、生产批件 29 张，形成 " 创新药 + 首仿药 + 后续研发梯队 " 多层次产品矩阵。重点管线司美格鲁肽注射液降糖适应症上市申请已通过国家药监局现场核查，预计 2027 年初获批上市；减重适应症Ⅲ期临床完成，预计 2026 年第四季度提交 NDA 申报。GLP 1R/GCGR 双靶点高潜力产品 P052 注射液减重效果表现突出，目前已获批临床。仿制药业务受集采、重点监控政策影响收入承压，集团稳步推进非核心业务剥离处置，保留具备竞争优势的品种，释放资金与管理资源集中投向医美、创新药两大主业，持续优化资产结构。财务方面，截至 2026 年 6 月末，集团现金、现金等价物及理财产品、定期存款合计 40.18 亿元，资金储备充足；2026 年实施股份回购 4200 万元，传递长期发展信心。3、管线进入集中收获期未来 1 3 年，公司管线进入集中收获期。医美板块，2026 年预计获批 2 3 个 HA 水光和填充类产品，申报 5 款胶原蛋白、再生类产品；2027 年预计获批 4 5 个新品，申报 10 余款管线；2028 年预计获批 10 款以上产品，覆盖高端轻医美全赛道。创新药板块，2027 年惠升生物司美格鲁肽注射液降糖适应症有望获批；轩竹生物多款自研双抗、小核酸产品陆续进入临床，肿瘤、免疫、代谢领域差异化管线持续落地。展望未来，四环医药将持续深耕 " 医美 + 创新药 " 双主业，以制药级严谨打磨产品与服务，巩固行业领先地位，为国内生物医药与医美行业高质量发展探索全新成长路径。追加内容本文作者可以追加内容哦 !

2026-09-01

·知乎专栏

四环医药中期亮眼！双主业共振，医美与创新药蓄势待发

用制药企业的严谨与创新，打造中国领先医美及生物制药企业。2026年上半年，四环医药整体经营业绩实现大幅跃升，核心财务指标全线向好，“医美+创新药”双主业协同发展格局进一步巩固。2026年上半年，公司总收益达到11.61亿元，同比增长1%；税前溢利3.66亿元，同比大幅提升133%；期内溢利2.13亿元，同比增长221%；本公司拥有人应占溢利2.25亿元，同比增长119%。业绩增长主要来自医美业务持续贡献核心盈利、创新药业务大幅减亏，叠加非经营性资产处置收益及投资收益共同推动。报告期内，“医美+创新药”两大核心业务占比已达到约80%，业务结构优化成效显著。分业务来看，医美业务收益6.93亿元，同比增长18.5%；轩竹业务收益0.69亿元，同比大增288%；惠升及其他业务收益1.92亿元，同比增长376%；仿制药业务受集采政策影响，实现收益2.06亿元，同比下降59%。1、医美板块继续担当集团核心利润引擎医美板块收入占比从51%提升至60%，同比增加9个百分点，经营质量持续优化。公司完成战略升级，从单纯销售产品转型为一站式解决方案服务商，构建起产品、研产、渠道三大核心竞争壁垒。产品端，乐提葆上半年终端销量稳居国内肉毒素市场第一梯队，童颜针新增6款规格获批，销量跻身国内行业前列；黑曜双波加速入院，连续5个月蝉联黄金微针品牌第一。企业搭建高低搭配水光产品体系，依靠精细化运营规避价格内卷，稳定产品毛利。研产层面，借助AI赋能研发，储备40余项在研优质管线，在PHA新材料赛道拥有独家技术优势；持续推进海外市场准入，将旗下医美运营主体渼颜空间持股比例提升至90%，配套管理层股权激励，自研产品启动欧盟市场注册，持续增厚归母利润。渠道方面，近200人的专业营销团队，联动9000余家合作医疗机构，业务覆盖全国34个省份、370余个城市，实现国内TOP500头部医美机构100%覆盖，1500余家重点核心医院纳入合作网络。童颜针再生产品覆盖超2000家机构，冻妍深度渗透千家下沉市场机构，渠道下沉成果显现。作为行业内唯一实现轻医美全品类合规布局的企业，四环医药手握60余款产品，覆盖填充、塑形、光电及皮肤管理全品类，拥有肉毒毒素、再生材料、动能素、双波射频微针、玻尿酸等完整产品线。在此基础上推出三大联合治疗方案：“回颜臻+冻妍”魔力童颜综合抗衰标杆方案；以“乐提葆”为核心的“乐葆+”全品类协同方案；“铂安润+倾妍+斯弗妍”组成的轮廓固定高阶抗衰方案。通过产品与设备组合，实现分层、分时、分部位精细化抗衰管理，跳出单品价格内卷，构筑差异化竞争壁垒。2、医药板块整体实现爆发式增长医药板块亏损同比大幅收窄32.1%。集团两大创新药平台轩竹生物、惠升生物均取得重要进展，企业正由Biotech加速迈向具备商业化兑现能力的Biopharma。轩竹生物作为集团核心创新药平台，2026上半年实现收入0.69亿元，同比增长288%。核心产品获得医保、权威指南及顶刊多重背书，医院渗透率持续提升。安久卫完成医保续约且价格保持稳定，RE、HP新适应症拓展打开长期市场空间；轩悦宁一线适应症获批，成为国内唯一覆盖乳腺癌全疗程的同类产品；轩菲宁成功获批，落地海外BD合作，贡献国际商业化增量。研发端，轩竹生物搭建大小分子+小核酸+临床多技术平台，依托自有TCE与AI平台开发多款双抗，已实现6项NDA申报。海外拓展方面，轩竹生物两款核心创新药落地中东北非独家授权，联动15国合作伙伴推进商业化落地。资本层面，轩竹生物顺利完成H股全流通并成功纳入港股通，股票流动性得到显著提升。惠升生物深耕糖尿病及并发症赛道，累计获批品种18个、获批规格27个、生产批件29张，形成“创新药+首仿药+后续研发梯队”多层次产品矩阵。重点管线司美格鲁肽注射液降糖适应症上市申请已通过国家药监局现场核查，预计2027年初获批上市；减重适应症Ⅲ期临床完成，预计2026年第四季度提交NDA申报。GLP 1R/GCGR双靶点高潜力产品P052注射液减重效果表现突出，目前已获批临床。仿制药业务受集采、重点监控政策影响收入承压，集团稳步推进非核心业务剥离处置，保留具备竞争优势的品种，释放资金与管理资源集中投向医美、创新药两大主业，持续优化资产结构。财务方面，截至2026年6月末，集团现金、现金等价物及理财产品、定期存款合计40.18亿元，资金储备充足；2026年实施股份回购4200万元，传递长期发展信心。3、管线进入集中收获期未来1 3年，公司管线进入集中收获期。医美板块，2026年预计获批2 3个HA水光和填充类产品，申报5款胶原蛋白、再生类产品；2027年预计获批4 5个新品，申报10余款管线；2028年预计获批10款以上产品，覆盖高端轻医美全赛道。创新药板块，2027年惠升生物司美格鲁肽注射液降糖适应症有望获批；轩竹生物多款自研双抗、小核酸产品陆续进入临床，肿瘤、免疫、代谢领域差异化管线持续落地。展望未来，四环医药将持续深耕“医美+创新药”双主业，以制药级严谨打磨产品与服务，巩固行业领先地位，为国内生物医药与医美行业高质量发展探索全新成长路径。

财报引进/卖出

2026-09-01

·allsci.com

Revelyx launches with recombinant botulinum toxin ready for Phase II readout

Nashville-based Revelyx Bio has launched as a clinical-stage company built around an exclusive license from China-based Chongqing Claruvis Pharmaceutical for YY003, a recombinant botulinum toxin type A (rBoNT/A) in a ready-to-use liquid formulation. Revelyx holds rights to develop and commercialize YY003 for aesthetic and therapeutic indications globally, excluding mainland China, Hong Kong, and Macau. Financial terms were not disclosed. YY003 is produced via recombinant expression in E. coli rather than conventional Clostridium botulinum fermentation, a manufacturing distinction Claruvis describes as offering greater control over neurotoxin identity and purity. The ready-to-use prefilled syringe format eliminates the reconstitution step required for currently approved leading botulinum toxin products. The US FDA cleared an investigational new drug application for YY003 in September 2024, and a Phase II study in adults with moderate-to-severe glabellar lines has been completed. Revelyx said it expects to report topline data in Q3 2026. Claruvis's platform credentials are anchored by Retoxin (YY001), a related lyophilized rBoNT/A that received approval from China's National Medical Products Administration in March 2026 — the first approved recombinant botulinum toxin type A anywhere in the world. YY003 is a distinct asset, differentiated from Retoxin primarily by its liquid formulation. Claruvis is separately advancing Retoxin in a Phase III trial in China for upper-limb spasticity secondary to stroke. The deal is Revelyx's founding transaction. The company is backed by NRL Capital, whose founding partner Xianghong Lin also founded BioBay, a major life sciences park in Suzhou. Dustin Sjuts, appointed CEO at launch, most recently served as president of Revance Therapeutics, where he oversaw the FDA approvals and US commercial launches of daxibotulinumtoxinA-lanm (Daxxify) for glabellar lines and cervical dystonia. The structure — a purpose-built Western company formed around a single-asset exclusive license from an Asian originator, with the originator retaining Greater China rights — resembles the model used by Evolus, which was built around an exclusive license from South Korea's Daewoong Pharmaceutical for prabotulinumtoxinA (Jeuveau) covering the US and Europe. In the botulinum toxin market, approved competitors — including onabotulinumtoxinA (Botox), abobotulinumtoxinA (Dysport), incobotulinumtoxinA (Xeomin), prabotulinumtoxinA (Jeuveau), and letibotulinumtoxinA (Letybo) — are all derived from bacterial fermentation and require reconstitution before injection. No rBoNT/A has been approved by the FDA. Revelyx has stated its goal is to deliver the first FDA-approved recombinant botulinum neurotoxin type A. Spot something wrong? Report an issue with this article

100 项与 A型肉毒毒素 (Hugel) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	A型肉毒毒素 (Hugel)	M03AX01	DB00083

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
眼睑痉挛	阿拉伯联合酋长国	Hugel, Inc.	2025-01-21
鱼尾纹	阿拉伯联合酋长国	Hugel, Inc.	2025-01-21
肌肉痉挛	阿拉伯联合酋长国	Hugel, Inc.	2025-01-21
眉间纹	中国	Hugel, Inc.	2020-10-21

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑卒中	临床3期	韩国	Hugel, Inc.	2013-06-01
上肢痉挛	临床3期	韩国	Hugel, Inc.	2013-06-01
良性基础型眼睑痉挛	临床3期	韩国	Hugel, Inc.	2008-04-01
额头皱纹	临床2期	奥地利	Croma-Pharma GmbH	2024-11-06
额头皱纹	临床2期	德国	Croma-Pharma GmbH	2024-11-06
咀嚼肌肥大	临床2期	韩国	Hugel, Inc.	2020-05-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03985982 (BLESSIII, CTgov)	临床3期	眉间纹	410	Botulinum Toxin A (Botulinum Toxin A)	膚衊鏇積製選鏇蓋襯顧 = 廠蓋齋艱淵蓋製觸醖網構積糧窪襯鑰鬱網積艱 (繭窪願鬱鹽鑰選網壓窪, 簾積範齋鑰淵蓋壓範廠 ~ 窪遞顧壓夢積糧廠憲繭) 更多	-	2025-06-05
				Placebo (Placebo)	膚衊鏇積製選鏇蓋襯顧 = 齋憲襯齋構壓範構遞範構積糧窪襯鑰鬱網積艱 (繭窪願鬱鹽鑰選網壓窪, 淵淵製鏇壓鹽簾顧鏇鑰 ~ 糧願鑰窪鹽鏇製獵艱鑰) 更多
NCT04763265 (H2H, CTgov)	临床2期	眉间纹	208	Botulinum toxin A "BoNT/A-DP" (Group A (n=100): BoNT/A-DP (20 U, 0.5 mL))	齋膚鏇壓鹹襯選廠遞齋(壓積簾壓艱願獵構鏇鏇) = 簾膚醖獵壓鑰簾齋選膚鹹齋願鹹鹽簾範簾繭蓋 (範廠醖膚淵夢壓襯簾獵, 鹽鹽簾蓋鹽膚積醖艱獵 ~ 鑰衊願願選廠壓繭觸壓) 更多	-	2025-03-18
				Botulinum toxin A "Botox Cosmetics" (Group B (n=100): Botox Cosmetic (20 U, 0.5 mL))	齋膚鏇壓鹹襯選廠遞齋(壓積簾壓艱願獵構鏇鏇) = 憲鏇獵憲淵網蓋築壓鹹鹹齋願鹹鹽簾範簾繭蓋 (範廠醖膚淵夢壓襯簾獵, 艱餘壓製憲襯壓艱獵鬱 ~ 淵簾夢願鏇鹹膚築鏇淵) 更多
NCT03408236 (Pubmed) 人工标引	临床3期	鱼尾纹	240	Letibotulinum toxin A	築鏇衊醖範廠夢網鏇觸(鏇糧遞範蓋繭鑰艱齋壓) = 衊鏇窪遞壓構衊積夢製廠鹹簾鬱製壓遞顧糧窪 (鏇選餘築積獵積鏇醖築 )	非劣	2021-07-01
				onabotulinum toxin A	築鏇衊醖範廠夢網鏇觸(鏇糧遞範蓋繭鑰艱齋壓) = 遞壓鹽淵築鬱醖糧製簾廠鹹簾鬱製壓遞顧糧窪 (鏇選餘築積獵積鏇醖築 )
NCT01915459 (Pubmed \| Clin Rehabil) 人工标引	临床3期	脑卒中 \| 上肢痉挛	187	letibotulinumtoxinA (mean ages were 56.81±9.49)	簾鬱糧膚襯築淵廠製觸(齋襯範鬱鹽製鹽淵鏇夢) = 糧獵遞鹹鏇壓艱積淵糧窪餘齋製淵鹽醖鹽製壓 (膚糧鹹選繭鑰齋繭製鹹, 0.61)	积极	2017-09-01
				letibotulinumtoxinA (mean ages were 56.93±11.93)	簾鬱糧膚襯築淵廠製觸(齋襯範鬱鹽製鹽淵鏇夢) = 餘衊憲繭顧鏇壓膚糧鑰窪餘齋製淵鹽醖鹽製壓 (膚糧鹹選繭鑰齋繭製鹹, 0.57)